Skip to main content
Log in

A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal caner

  • Original Article
  • 5-Fluorouracil, Interferon, Colorectal Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Modulation of 5-fluorouracil (FUra) using leucovorin (LV) is a standard treatment approach in patients with metastatic colorectal cancer. Modulation of FUra with interferon alfa has also shown some promise. Laboratory data have demonstrated increased cytotoxicity when FUra is combined with both LV and interferon. The current study examined the effects of double modulation of FUra using LV and interferon. Patients with measurable advanced colorectal cancer received bolus FUra 375 mg/m2 plus LV 20 mg/m2 daily for 5 days, repeated every 28 days. Recombinant human interferon alfa-2a, 3 million IU/m2 subcutaneously, was given daily on the days of chemotherapy then three times weekly. There was one complete response and nine partial responses (10/41) seen for an overall response rate of 24% (95% CI 12.0–40.0%). Overall, 70% of patients experienced one or more episodes of nonhematologic toxicity of grade 3 or more. Weight loss was common, with a mean decrease of 2.9 kg over the first two months (P<0.0001). Improvements in tumor-related symptoms were balanced by increased fatigue and a deterioration in body weight and performance status. There was no evidence of progressive changes in FUra metabolism from interferon usage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Advanced colorectal cancer meta-analysis project (1992) Modulation of FUra by leucovorin in patients with metastatic colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896–903

    Google Scholar 

  2. Bruckner HW, Motwanti BT (1991) Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol 18: 443–461

    Google Scholar 

  3. Bukowski RM, Inoshita G, Yalavarthi P, et al (1992) A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma. Cancer 69: 889–892

    Google Scholar 

  4. Burkputt AR, Boyd MR (1980) Measurement of 5-fluorouracil in plasma by HPLC. Ann Biochem 106: 432–437

    Google Scholar 

  5. Cascinu S, Fedeli A, Fedeli SL, et al (1992) Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. Ann Oncol 3: 489–491

    Google Scholar 

  6. Chu E, Koeller DM, Johnston PG, Zinn S, Allegra C (1993) Regulation of thymidylate synthase in human colon cancer cells treated with FUra and interferon gamma. Mol Pharmacol 43: 527–533

    Google Scholar 

  7. Danhauser LL, Freimann JH Jr, Gilchrist TL, Gutterman JU, Hunter CY, Yeomans AC, Markowitz AB (1993) Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol 11: 751–761

    Google Scholar 

  8. Erlichman C, Fine S, Wong A, Elkahim T (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 3: 469–475

    Google Scholar 

  9. Grem JL, Jordon E, Robson ME, et al (1993) Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 11: 1737–1745

    Google Scholar 

  10. Houghton JA, Adkins DA, Rahman A, Houghton PJ (1991) Interaction between 5-fluorouracil, [6RS] leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells. Cancer Commun 3: 225–231

    Google Scholar 

  11. Houghton JA, Morton CL, Adkins DA, Rahman A (1993) Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells. Cancer Res 53: 4243–4250

    Google Scholar 

  12. Kemeny N, Younes A (1992) Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: The Memorial Sloan-Kettering Experience. Semin Oncol 19: 180–184

    Google Scholar 

  13. Kocha W and the CORFU-A collaborative group (1993) FUra plus interferon versus FUra plus LV in metastatic colorectal cancer-results of a multicentre, multinational phase III study. Proc Am Soc Clin Oncol 12: 562

    Google Scholar 

  14. Labianca R, Pacera G, Tedeschi L, Dallavalle G, Luporini A, Luporini G (1992) High dose alpha-2b interferon + folinic acid in the modulation of 5-fluorouracil. A phase II study in advanced colorectal cancer with evidence of an unfavourable cost/benefit ratio. Tumori 78: 32–34

    Google Scholar 

  15. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 204–214

    Google Scholar 

  16. Moore MJ, Kaizer L, Erlichman C, Fine S (1991) A phase I clinical and pharmacologic study of 5-fluorouracil, leucovorin and interferon. Proc Am Soc Clin Oncol 10: 313

    Google Scholar 

  17. O'Connell MJ (1989) A phase III trial of FUra and leucovorin in the treatment of advanced colorectal cancer. Cancer 63: 1026–1030

    Google Scholar 

  18. Pazdur R, Ajani JA, Patt YZ, Gomez J, Bready B, Levin B (1993) Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer 71: 1214–1218

    Google Scholar 

  19. Pittman K, Perren T, Ward U, Primrose J, Slevin M, Patel N, Selby P (1993) Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon. Ann Oncol 4: 515–516

    Google Scholar 

  20. Punt CJ, Burghouts JT, Croles JJ, Liessum PA van, deMulder PHM, Kamm Y (1993) Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study. Cancer 72: 2107–2111

    Google Scholar 

  21. Silgals RM, Ahlgen JD, Neefe JR, Rothman J, Rudnick S, Galicki FP, et al (1984) A phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer. Cancer 54: 2257–2261

    Google Scholar 

  22. Sobrero A, Nobile MT, Guglielmi A, et al (1992) Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer. Eur J Cancer 28A: 850–852

    Google Scholar 

  23. Sparano JA, Wadler S, Diasio RB, Zhang R, Lu Z, Schwartz EL, Einzig A, Wiernik PH (1993) Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol 11: 1609–1617

    Google Scholar 

  24. Wadler S, Goldman M, Lyver A, Wiernik P (1990) Phase I trial of 5-fluorouracil and recombinant alpha-2a interferon in patients with advanced colorectal cancer. Cancer Res 50: 2056–2059

    Google Scholar 

  25. Weh HJ, Platz D, Braumann D, et al (1992) Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal cancer. Eur J Cancer 28A: 1820–1823

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

This work was supported in part by a grant from Hoffman LaRoche Canada

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moore, M.J., Kaizer, L., Erlichman, C. et al. A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal caner. Cancer Chemother. Pharmacol. 37, 86–90 (1995). https://doi.org/10.1007/BF00685633

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685633

Key Words

Navigation